SYNH Stock Recent News

TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce Michele Rath as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, LLC, a wholly owned subsidiary of the Company, leading and managing Scienture, LLC's commercial operations. Under Ms. Rath's leadership, Scienture, LLC has formalized a strategic relationship with Syneos Health Commercial Services, LLC (“Syneos Health”), a premier biopharmaceutical solutions organization, by executing a Master Commercial Services Agreement with Syneos Health (the “MCSA”). Pursuant to the MCSA, Syneos Health will serve as Scienture, LLC's Contract Sales Organization (CSO). This collaborat

Colin Shannon Appointed Executive Chairman Seasoned Executive Further Strengthens Company's Leadership Team MORRISVILLE, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Costa Panagos as CEO and a member of the Company's Board of Directors, effective immediately.

Syneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities.

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syneos Health (SYNH) partners with uMotif to deliver the patient-centric eClinical platform.

Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

Syneos Health (SYNH) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $1.01 per share a year ago.

Syneos Health (NASDAQ: SYNH ) stock is on the rise Wednesday as investors react to news of a $7.1 billion acquisition deal. A group of investors led by Elliott Investment Management intend to take the healthcare company private for a price of $43 per share.

The sale of Syneos Health comes as the company faces muted spending from drug developers for its clinical-research services.